Sebastien Plouffe - Defence Therapeutics Pres CEO
| DTCFF Stock | USD 0.41 0.00 0.00% |
Insider
Sebastien Plouffe is Pres CEO of Defence Therapeutics
| Age | 51 |
| Phone | 514 947 2272 |
| Web | https://defencetherapeutics.com |
Defence Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.7905) % which means that it has lost $1.7905 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.1532) %, meaning that it generated substantial loss on money invested by shareholders. Defence Therapeutics' management efficiency ratios could be used to measure how well Defence Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dr MBA | Blueprint Medicines Corp | 54 | |
| Robert Weingarten | Lixte Biotechnology Holdings | 72 | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| MS MBA | XOMA Corporation | 67 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Eric JD | Lixte Biotechnology Holdings | 45 | |
| Sigal Arad | Enlivex Therapeutics | N/A | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| Pr MD | Enlivex Therapeutics | 68 | |
| Alexis AM | Blueprint Medicines Corp | 52 | |
| Oren Hershkovitz | Enlivex Therapeutics | 47 | |
| Carl Langren | Lumos Pharma | 69 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| Thomas Schaible | Fortress Biotech | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
Management Performance
| Return On Equity | -4.15 | |||
| Return On Asset | -1.79 |
Defence Therapeutics Leadership Team
Elected by the shareholders, the Defence Therapeutics' board of directors comprises two types of representatives: Defence Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Defence. The board's role is to monitor Defence Therapeutics' management team and ensure that shareholders' interests are well served. Defence Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Defence Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Moutih Rafei, VP Director | ||
| Sebastien Plouffe, Pres CEO | ||
| Carrie Cesarone, Co Sec | ||
| Simon Beaudoin, Chief Officer |
Defence Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Defence Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.15 | |||
| Return On Asset | -1.79 | |||
| Current Valuation | 60.32 M | |||
| Shares Outstanding | 37.85 M | |||
| Shares Owned By Insiders | 5.26 % | |||
| Price To Book | 36.71 X | |||
| EBITDA | (7.32 M) | |||
| Net Income | (7.34 M) | |||
| Cash And Equivalents | 506.7 K | |||
| Cash Per Share | 0.01 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Defence OTC Stock
Defence Therapeutics financial ratios help investors to determine whether Defence OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Defence with respect to the benefits of owning Defence Therapeutics security.